|
Announcement Date
|
Date of Meeting
|
Purpose
|
|
11-May-2023
|
26-May-2023
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2023 inter alia to consider and approve
1. To approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31 2023.
2. To consider and recommend final dividend if any on the equity shares of the Company for the financial year ended March 31 2023.
With reference to the intimation of Board meeting submitted on May 11, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. May 26, 2023 which commenced at 10:40 a.m. and ended at 02:35 p.m., wherein the Board has, inter-alia,
1. Approved Financial Results for the fourth quarter and year ended March 31, 2023
2. Recommended Final Dividend for financial year 2022-23
(As Per BSE Announcement dated on 26.05.2023)
The Board of Directors at their meeting held on May 26, 2023, inter alia, have approved the following: 1. Appointment of Mr. Rolf Hoffmann as an Independent Director 2. Appointment of Mr. Aalok Shanghvi as a Whole-time Director
(As Per BSE Announcement Dated on 27.05.2023)
|
|
16-Jan-2023
|
31-Jan-2023
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2023 inter alia to consider and approve 1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2022
2. Declaration of Interim Dividend for the financial year 2022-23
With reference to the intimation of Board meeting submitted on January 16, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 31, 2023 which commenced at 10:00 a.m. and ended at 01:20 p.m. The Board has, inter-alia,
Approved Financial Results for the quarter and nine months ended December 31, 2022
Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company and its subsidiaries for the quarter and nine months ended December 31, 2022, along with the Limited Review Reports thereon.
With reference to the intimation of Board meeting submitted on January 16, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 31, 2023 which commenced at 10:00 a.m. and ended at 01:20 p.m. The Board has, inter-alia, Considered and approved declaration of Interim Dividend for the financial year 2022-23 An interim dividend of Rs. 7.50/- (Rupees seven and paise fifty only) per equity share of Re. l/- (Rupee one only) each of the Company for the financial year 2022-23. Further, as already intimated on January 16, 2023, the Record Date for entitlement of interim dividend for the financial year 2022-23 is February 08, 2023. The interim dividend shall be paid on or before February 20, 2023.
With reference to the intimation of Board meeting submitted on January 16, 2023, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 31, 2023 which commenced at 10:00 a.m. and ended at 01:20 p.m. The Board has, inter-alia, Noted the retirement of Mr. Kalyanasundaram Subramanian as Whole-time Director effective from February 13, 2023 The term of Mr. Kalyanasundaram Subramanian (DIN: 00179072), Whole-time Director would end on February 13, 2023, and accordingly he shall retire from the Directorship of the Company with effect from that date.
(As Per BSE Announcement Dated on 31/01/2023)
|
|
10-Oct-2022
|
01-Nov-2022
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2022 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2022
|
|
12-Jul-2022
|
29-Jul-2022
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2022 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2022
With reference to the intimation of Board meeting submitted on July 12, 2022, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. July 29, 2022 which commenced at 10:00 a.m. IST and ended at 01:25 p.m. IST.
The Board has, inter-alia, approved Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2022.
(As per BSE Announcement Dated on 29/07/2022)
|
|
12-May-2022
|
30-May-2022
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve i. Annual Audited Standalone and Consolidated Financial Results; and
ii. Recommendation of final dividend if any.
Attached
(As Per BSE Announcement dated on 30.05.2022)
|
|
17-Jan-2022
|
31-Jan-2022
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Monday January 31 2022 to inter alia consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2021.
Further kindly note that pursuant to the Companys Code of Conduct for Prevention of Insider Trading the window closure for trading by Designated Persons commenced on January 01 2022 and shall end on February 02 2022 i.e. after 48 hours of the declaration of financial results of the Company on January 31 2022.
This is for your information and dissemination.
This is to inform you that the Board of Directors of the Company, at its meeting scheduled to be held on Monday, January 31, 2022, will inter-alia consider declaration of Interim Dividend on the equity shares of the Company, for the financial year 2021-22.
(As Per BSE Announcement dated on 25.01.2022)
As per the letter attached
(As per BSE Announcement Dated on 31/01/2022)
Sun Pharmaceutical Industries Ltd has informed BSE that the Company has fixed February 10, 2022 as the Record Date for the purpose of Payment of Interim Dividend.
The payment of the interim dividend would be made to the eligible shareholders on or before February 22, 2022.
(As Per BSE Announcement dated on 01.02.2022)
|
|
12-Oct-2021
|
02-Nov-2021
|
Quarterly Results
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2021 ,inter alia, to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, November 02, 2021 to inter alia consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021.
Further, kindly note that pursuant to the Company''s Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons, commenced on October 01, 2021, and shall end on November 04, 2021 i.e. after 48 hours of the declaration of financial results of the Company on November 02, 2021.
This is for your information and dissemination.
The Board of Directors of the Company at its meeting held today i.e. November 02, 2021 has inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021.
Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we enclose herewith the following as 'Annexure':
a) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021.
b) Limited Review Report of the Statutory Auditors of the Company on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021.
The meeting of the Board of Directors of the Company commenced at 10:30 a.m. and concluded at 01:10 p.m.
(As Per BSE Announcement Dated 02.11.2021)
|
|
13-Jul-2021
|
30-Jul-2021
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2021 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021
The Board of Directors of the Company at its meeting held today i.e. July 30, 2021 has inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021.
Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we enclose herewith the following as 'Annexure':
a) Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30, 2021.
b) Limited Review Report of the Statutory Auditors of the Company on Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2021.
The meeting of the Board of Directors of the Company commenced at 10.15 a.m. and concluded at 1:45 p.m.
(As per BSE Announcement Dated on 30/07/2021)
|
|
10-May-2021
|
27-May-2021
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2021 ,inter alia, to consider and approve (i) Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2021. (ii) recommendation of final dividend for the year ended March 31, 2021 subject to the approval of the shareholders at the ensuing 29th Annual General Meeting.
As per letter attached
(As Per BSE Announcement dated on 27.05.2021)
|
|
04-Jan-2021
|
29-Jan-2021
|
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2021 ,inter alia, to consider and approve This is to inform you that the meeting of the Board of Directors of the Company will be held on Friday, January 29, 2021 to inter alia consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2020. Further, kindly note that pursuant to the Company''s Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons, commenced on January 01, 2021, and shall end on January 31, 2021 i.e. after 48 hours of the declaration of financial results of the Company on January 29, 2021. This is for your information and record.
The Board of Directors of the Company, at its meeting scheduled to be held on Friday, January 29, 2021, will inter-alia consider declaration of Interim Dividend on the equity shares of the Company, for the financial year 2020-21
(AS Per BSE Announcement Dated on 21.01.2021)
1)Approval of Unaudited Financial Statements for the quarter and nine months ended December 31, 2020; 2) Declaration of an Interim Dividend for the financial year ending on March 31, 2021 and fixing of Record Date for the same; and 3) Re-appointment of Mr. Kalyanasundaram Subramanian (DIN: 00179072) as Whole-time Director for further period of two years w.e.f. February 14, 2021.
The Board at its meeting held today, declared an interim dividend of Rs. 5.50/- (Rupees Five and paise fifty only) per equity share of Re. 1/- each of the Company for the financial year ending on March 31, 2021.
Further, the Board of Directors of the Company has fixed Wednesday, February 10, 2021 as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive payment towards Interim Dividend of the Company for the financial year 2020-21 declared today. The payment of the interim dividend would be made to the eligible shareholders on or before February 19, 2021.
1) Approval of Unaudited Financial Statements for the quarter and nine months ended
December 31, 2020;
2) Declaration of an Interim Dividend for the financial year ending on March 31, 2021
and fixing of Record Date for the same; and
3) Re-appointment of Mr. Kalyanasundaram Subramanian (DIN: 00179072) as
Whole-time Director for further period of two years w.e.f. February 14, 2021.
The Board at its meeting held today, declared an interim dividend of Rs. 5.50/- (Rupees Five and paise fifty only) per equity share of Re. 1/- each of the Company for the financial year ending on March 31, 2021.
Further, the Board of Directors of the Company has fixed Wednesday, February 10, 2021 as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive payment towards Interim Dividend of the Company for the financial year 2020-21 declared today. The payment of the interim dividend would be made to the eligible shareholders on or before February 19, 2021.
(As Per BSE Announcement Dated on 1/29/2021)
|
|
|
|